Table 4.
Summary of the subgroup meta-analysis results
| Analysis (OS) | n | References | Fixed-effect model | Random-effect model | Heterogeneity | |||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||
| HR (95% CI) | P | HR (95% CI) | P (Z-test) | I2 (%) | Ph | |||
| Subgroup 1 | ||||||||
| IDH-wildtype | 5 | [8,14,16,23,25] | 1.69 (1.36-2.10) | 0.000 | 1.76 (1.42-2. 17) | 0.000 | 22.5 | 0.271 |
| IDH-mutant | 4 | [19,23,24,25] | 0.73 (0.57-0.93) | 0.012 | 0.70 (0.52-0.95) | 0.023 | 22.3 | 0.277 |
| Subgroup 2 | ||||||||
| GBM | 8 | [7,10,16,17,20,21,22,27] | 1.47 (1.31-1.65) | 0.000 | 1.54 (1.28-1.85) | 0.000 | 49.8 | 0.021 |
| Astrocytoma | 4 | [12,16,23,26] | 2.97 (1.97-4.31) | 0.000 | 2.91 (1.97-4.31) | 0.000 | 0.00 | 0.548 |
| Subgroup 3 | ||||||||
| Adult | 8 | [7,8,12,13,16,18,21,24] | 1.62 (1.36-1.92) | 0.000 | 1.62 (1.36-1.92) | 0.000 | 0.00 | 0.451 |
| Adult and children | 3 | [9,11,15] | 1.42 (0.97-2.07) | 0.072 | 1.42 (0.97-2.07) | 0.072 | 0.00 | 0.840 |
| Subgroup 4 | ||||||||
| C228T | 4 | [10,18,22,27] | 1.32 (1.06-1.64) | 0.012 | 1.72 (1.00-2.97) | 0.052 | 79.6 | 0.001 |
| C250T | 4 | [10,18,22,27] | 1.50 (1.15-1.95) | 0.003 | 1.67 (1.13-2.47) | 0.010 | 41.4 | 0.146 |
| Subgroup 5 | ||||||||
| Asian | 10 | [9,11,12,13,15,16,18,19,23,26] | 1.64 (1.38-1.96) | 0.000 | 1.65 (1.35-1.80) | 0.001 | 51.7 | 0.010 |
| Caucasian | 11 | [7,8,10,14,17,20,21,22,24,25,27] | 1.39 (1.27-1.52) | 0.000 | 1.49 (1.28-1.74) | 0.000 | 56.4 | 0.014 |
| Subgroup 6 | ||||||||
| pTERT mutation | 21 | [7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27] | 1.44 (1.33-1.56) | 0.000 | 1.56 (1.35-1.80) | 0.000 | 57.2 | 0.001 |
| TERT expression | 7 | [28,29,30,31,32,33,34] | 1.06 (1.04-1.08) | 0.000 | 1.11 (1.04-1.18) | 0.001 | 67.1 | 0.003 |
n=Number of studies; Ph=P values of Q-test for heterogeneity test. HR=Hazard ratio; CI=Confidence interval; OS=Overall survival; TERT=Telomerase reverse transcriptase; GBM=Glioblastoma; IDH=Iso-citrate dehydrogenase